# A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

> **NCT05891249** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 85 (estimated)

## Conditions studied

- Anemia

## Interventions

- **BIOLOGICAL:** Luspatercept

## Key facts

- **NCT ID:** NCT05891249
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2028-12-16
- **Final completion:** 2028-12-16
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891249, "A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05891249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*